Literature DB >> 9482909

The role of inducible nitric oxide synthase in the host response to Coxsackievirus myocarditis.

C Zaragoza1, C Ocampo, M Saura, M Leppo, X Q Wei, R Quick, S Moncada, F Y Liew, C J Lowenstein.   

Abstract

The host response to Coxsackievirus infection is complex, including T lymphocytes, B lymphocytes, natural killer cells, and macrophages. Although Coxsackievirus infection induces expression of inducible nitric oxide synthase (NOS2; EC 1.14.13.39) in macrophages, the precise role of NOS2 in the host response to Coxsackievirus myocarditis has been unclear. We show, by using mice homozygous for a disrupted NOS2 allele, that Coxsackievirus replicates to higher titers in NOS2(-/-) mice, that the host lacking NOS2 clears virus more slowly than the wild-type host, and that myocarditis is much more severe in infected NOS2(-/-) mice. These data show that NOS2 is crucial for the host response to Coxsackievirus in the mouse.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9482909      PMCID: PMC19377          DOI: 10.1073/pnas.95.5.2469

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

1.  Coxsackievirus B3 murine myocarditis: wide pathologic spectrum in genetically defined inbred strains.

Authors:  A Herskowitz; K W Beisel; L J Wolfgram; N R Rose
Journal:  Hum Pathol       Date:  1985-07       Impact factor: 3.466

2.  Age-dependent pathogenicity of group B coxsackieviruses in Swiss-Webster mice: infectivity for myocardium and pancreas.

Authors:  R Khatib; J L Chason; B K Silberberg; A M Lerner
Journal:  J Infect Dis       Date:  1980-03       Impact factor: 5.226

3.  Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice.

Authors:  L J Wolfgram; K W Beisel; A Herskowitz; N R Rose
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

4.  Macrophages in mice acutely infected with lymphocytic choriomeningitis virus are primed for nitric oxide synthesis.

Authors:  E A Butz; B S Hostager; P J Southern
Journal:  Microb Pathog       Date:  1994-04       Impact factor: 3.738

5.  Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3.

Authors:  S A Huber; B Pfaeffle
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

6.  Induction of myocardial nitric oxide synthase by cardiac allograft rejection.

Authors:  X Yang; N Chowdhury; B Cai; J Brett; C Marboe; R R Sciacca; R E Michler; P J Cannon
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

7.  Coxsackie B3 virus can replicate in cultured human foetal heart cells and is inhibited by interferon.

Authors:  R Kandolf; A Canu; P H Hofschneider
Journal:  J Mol Cell Cardiol       Date:  1985-02       Impact factor: 5.000

8.  Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation.

Authors:  J B Mannick; K Asano; K Izumi; E Kieff; J S Stamler
Journal:  Cell       Date:  1994-12-30       Impact factor: 41.582

9.  Mice devoid of interferon regulatory factor 1 (IRF-1) show normal expression of type I interferon genes.

Authors:  L F Reis; H Ruffner; G Stark; M Aguet; C Weissmann
Journal:  EMBO J       Date:  1994-10-17       Impact factor: 11.598

10.  Role of interferon regulatory factor 1 in induction of nitric oxide synthase.

Authors:  E Martin; C Nathan; Q W Xie
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  23 in total

Review 1.  Influence of myocarditis on left ventricular function.

Authors:  K L Baughman
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

2.  Nitric oxide inhibits HIV tat-induced NF-kappaB activation.

Authors:  F Chen; Y Lu; V Castranova; Y Rojanasakul; K Miyahara; Y Shizuta; V Vallyathan; X Shi; L M Demers
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

3.  Sustained nitric oxide synthesis contributes to immunopathology in ongoing myocarditis attributable to interleukin-10 disorders.

Authors:  Gudrun Szalay; Martina Sauter; Joachim Hald; Andreas Weinzierl; Reinhard Kandolf; Karin Klingel
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

Review 4.  Targeting matrix metalloproteinase activity and expression for the treatment of viral myocarditis.

Authors:  Reid G Hendry; Leanne M Bilawchuk; David J Marchant
Journal:  J Cardiovasc Transl Res       Date:  2014-01-01       Impact factor: 4.132

5.  Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected mice.

Authors:  Roland Zell; René Markgraf; Michaela Schmidtke; Matthias Görlach; Axel Stelzner; Andreas Henke; Holger H Sigusch; Brigitte Glück
Journal:  Med Microbiol Immunol       Date:  2003-09-26       Impact factor: 3.402

6.  vig-1, a new fish gene induced by the rhabdovirus glycoprotein, has a virus-induced homologue in humans and shares conserved motifs with the MoaA family.

Authors:  P Boudinot; P Massin; M Blanco; S Riffault; A Benmansour
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

Review 7.  Diagnosis and treatment of viral myocarditis.

Authors:  Jason C Schultz; Anthony A Hilliard; Leslie T Cooper; Charanjit S Rihal
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

8.  Identification of nitric oxide synthase 2 as an innate resistance locus against ectromelia virus infection.

Authors:  G Karupiah; J H Chen; C F Nathan; S Mahalingam; J D MacMicking
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

9.  Peroxynitrite inhibition of Coxsackievirus infection by prevention of viral RNA entry.

Authors:  Elizaveta Padalko; Tomokazu Ohnishi; Kenji Matsushita; Henry Sun; Karen Fox-Talbot; Clare Bao; William M Baldwin; Charles J Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-30       Impact factor: 11.205

10.  The role of nitric oxide in mycobacterial infections.

Authors:  Chul-Su Yang; Jae-Min Yuk; Eun-Kyeong Jo
Journal:  Immune Netw       Date:  2009-04-30       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.